AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.
Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
Layoffs are reported to be in the offing.
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Medibid users auction up care in exchange for a low price.
The PBM dropped 25 more drugs from its formulary.
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.
UnitedHealthcare finds drug costs more than doubled.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
Health insurers and pharmacies signed a letter asking the FDA to require biosimilars and branded biologics to share the same name.
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.
The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
Patients will now be able to submit specialty prescriptions at the national chain's retail stores.
Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.
The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."
The drugmaker sent Olysio + Sovaldi to regulators for an additional indication in HCV patients with liver scarring.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
- Deloitte taps Havas Lynx's Mickelberg as MD
- Five things for pharma marketers to know: Wednesday, February 22, 2017
- Five things for pharma marketers to know: Thursday, February 23, 2017
- Five things for pharma marketers to know: Tuesday, February 21, 2017
- How VAYA Pharma used Facebook ads for its ADHD campaign